14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
AVDL vs PAHC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Phibro Animal Health Corporation Class A (PAHC) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas PAHC carries 65.9/100 (BUY) at $33.29 (10.0x Forward P/E, 12.7% operating margin).
Growth vs. Quality Trade-Off: PAHC earns the overall head-to-head edge with a stronger Unified Composite Score (65.9/100 BUY vs. AVDL 62.9/100 BUY) and 1.04β · 55% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile PAHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs PAHC. Trailing 12-month operating profitability (AVDL 2.5% vs PAHC 12.7%) and valuation multiples (AVDL 28.8x vs PAHC 10.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.4B market capitalization and 12.7% operating margin.
OpEx & R&D Reinvestment20.6% of Rev ($317M)
90D Engineering Disclosures0 Published
Investor FAQ AVDL vs PAHC Key Questions & Quantitative Answers
As of Nov 20, 2026, Phibro Animal Health Corporation Class A (PAHC) is the stronger overall head-to-head candidate over Avadel Pharmaceuticals plc Ordinary Share (AVDL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas PAHC carries 65.9/100 (BUY) at $33.29 (10.0x Forward P/E, 12.7% operating margin). Growth vs. Quality Trade-Off: PAHC earns the overall head-to-head edge with a stronger Unified Composite Score (65.9/100 BUY vs. AVDL 62.9/100 BUY) and 1.04β · 55% Vol risk profile, whereas AVDL leads top-line expansion (+54.9% YoY revenue growth, 0.07x PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile PAHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with PAHC at +6.3% YoY revenue growth and +10.8% YoY earnings growth on $1.54B TTM revenue (33.3% gross margin, 12.7% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $1.54B for PAHC. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 20.6% of Rev ($317M) (0 disclosures) for PAHC.
PAHC screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas PAHC trades at 10.0x Forward P/E, 14.2x Trailing P/E, 1.68x PEG, and 1.4x EV/Revenue (1.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus PAHC (28.2% ROE) capital efficiency.
In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, PAHC carries 70.3% implied volatility (9th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.